Swayampakula Ramakanth, an analyst from H.C. Wainwright, maintained the Buy rating on Eton Pharmaceuticals (ETON – Research Report). The associated price target remains the same with $33.00.
Swayampakula Ramakanth’s rating is based on Eton Pharmaceuticals’ strategic initiatives and growth potential. The company is set to launch ET-400, a hydrocortisone oral solution, in 2025, which is expected to address issues with the current ALKINDI SPRINKLE formulation and drive significant revenue growth. The management’s focus on organic growth, internal pipeline development, and potential acquisitions further supports the company’s long-term growth prospects.
Additionally, Eton Pharmaceuticals is working on expanding the market potential for Increlex, a therapy for growth failure in pediatric patients. The company has been actively engaging with the pediatric endocrinology community to increase awareness and usage of Increlex, which has already shown positive results. Furthermore, there is potential for label expansion, which could significantly increase the target patient population and revenue. These factors combined suggest a promising outlook for Eton Pharmaceuticals, justifying the Buy rating.
According to TipRanks, Ramakanth is a 3-star analyst with an average return of 2.2% and a 35.07% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Eton Pharmaceuticals, Vericel, and Delcath Systems.